United States: Biomanufacturing Technology Summit 2015 In Maryland: Bioanalytics Guiding Quality, Where Increased Collaboration Could Lead To Faster And Greater Discoveries

Last Updated: July 5 2015
Article by Brian J. Malkin

On June 25, 2015, the Institute for Bioscience and Biotechnology Research (IBBR), the National Institute of Standards and Technology (NIST), and the University of Maryland (UM) put on its second Biomanufacturing Technology Summit, "Manufacturing Science Analytics: Predictors of Biotherapeutic Product Quality", in Rockville, Maryland.  McGuireWoods LLP was a sponsor of this important Summit and had Brian Malkin and TaeSoo "Sean" Kim on hand to interact with speakers and attendees.

Thomas R. Fuerst, Ph.D., Director IBBR, and William Bentley, Ph.D., Distinguished Professor and Chair, Department of Bioengineering, UMD, set the stage for the Summit as a place to discuss new bioanalytical testing for predicting the quality attributes of biological products including biosimilar versions of those products.

Then FDA's Steven Kozlowski, M.D., Director, Office of Biotechnology Products, took center stage, where he said that in terms of analytics and biological products, there is always a need to strive for being better, challenging the current state of analytics that control quality as "not good enough." For the same sponsor, changes in biological product manufacturing are driven by the quality control of comparability; for a different sponsor, the quality control goal is biosimilarity. Traditionally, FDA has thought about quality as a set of specifications, with changes that may be made either simultaneous to agency notification (changes being effected – 30 days), following preapproval supplements, or in annual reports. FDA has been concerned, Koslowski explained, that industry was confused with what were the "established conditions" in an application or license that represents the core chemistry, manufacturing and controls for an approved application (new drug application (NDA) or abbreviated new drug application (ANDA)) or license (biologics license application (BLA)). So last month, FDA issued draft guidance on the agency's thoughts on "established conditions" in the guidance, " Established Conditions: Reportable CMC Changes for Approved Drug and Biological Products". Here, "established conditions" is defined as "the description of the product, manufacturing process, facilities and equipment, and elements of the associated control strategy, as defined in an application, that assure product performance and quality of the approved product."

Along these lines, Kozlowski described FDA's evolving thoughts about the established conditions for biological products. Because the landscape of analytics to choose from continues to change, initial process or release analytics may change over time, resulting in a reordering of the risk ranking of quality attributes. As a result, it is critical to retain useful samples for comparative studies in anticipation of life cycle changes to compare products made with older and newer processes in view of the changing analytic tools. And it is increasingly important for manufacturers to integrate analytics into manufacturing to watch for potential changes in biological characterization (biocreep), as well as developing biosimilar products, where the analytics drive the required animal and clinical studies.

Regarding biosimilars, Kozlowski said that FDA has received over 80 meeting requests for 15 proposed biosimilar products, which have resulted in several filed and publicly-disclosed biosimilar applications and one approved biosimilar product. Kozlowski said that in terms of analytics, he believes that there is a need for a consortium of biosimilar companies to work together to help develop common and current analytics to help all of the biological product companies meet their goals more quickly.

The morning session featured additional presentations on real-time predictive models: bio-sensors and bio-predictors. Govind Rao, Ph.D., Professor of Chemical and Biochemical Engineering, Director of the Center for Advanced Sensor Technology, UM. Rao explained that it is critical to monitor biological manufacturing from start to final product; if not, "it would be like having a child and not monitoring it until it went to college." Biosensors, such as oxygen levels, Rao observed, help to determine the window of optimal growth conditions for fermentation bioprocessing. Along these lines, Rao noted that there is a need to develop smaller-scale models that help to simulate ramp-up conditions for large-scale production for the final product.

Later, Patrick Swann, Ph.D. Senior Director, Technical Development, Biogen, discussed how different bioanalytics are utilized at various processing stages, including intermediate products or process-related impurities monitored, such as acidic isoforms that can limit shelf life, as part of quality-by-design. Alexion's Kyle Zingaro, Ph.D., Development Scientist I, Upstream Development, then discussed how improved bioanalytic characterizations lead to accelerated process development and platform development with the goals of quality, robustness, raw material supply chain, scalability, productivity, and cost effectiveness. Zingaro described how the need for a better connection between biophysical quality and clinical safety and efficacy drives to a consensus development of a biological fingerprint, which will be increasingly important.

FDA's Lieutenant Commander Cyrus Agarabi, Ph.D., Senior Regulatory Researcher, Center for Drug Evaluation and Research, rounded out the morning's program. Agarabi described how FDA's internal regulatory research, including biological product analytical testing, helps to support policy development and biotechnology review decisions. Agarabi encouraged industry to collaborate more with less compartmentalization of knowledge by sharing information about equipment and use for integrated bioprocessing systems to drive product quality in-line, on-line, and at-line with continuous manufacturing. As an example, nutrient analysis is often critical to affect cell viability and reliability, which can be integrated into bioreactors and autosamplers, including continuous sampling of media and cell membrane charges (indicating a cell is alive) to maximize cell harvest.

The afternoon focused on computational and analytical methods for predictive final product characterization. Michael Tarlov, Ph.D., Division Chief, Biomolecular Measurement Division, Material Measurement Laboratory, NIST, said that NIST is looking for more collaboration in the development of bioanalytical predictors for biological product quality. Steven Rose, Associate Director, Upstream BioProcess Engineering, MedImmune, described how MedImmune has been linking certain predictive cell culture scaling methods, e.g., pH and the carbon dioxide equilibrium to optimize inputs. Then Elizabeth M. Topp, Ph.D., Head, Department of Industrial and Physical Pharmacy, Purdue University, described how mass spectroscopy and other analytical methods may be used to test lyophilized biological products to obtain test and accelerated stability data, which has been conducted as part of a NIST consortium. Merck's Marina Goldfeld, Associate Principal Scientist, described an innovative real-time measurement tool for glycerol, methanol, and biomass in a particular fermentation culture. And then Florian M. Wurm, Ph.D., Honorary Professor, Swiss Federal Institute of Technology and Founder and CEO, ExcellGene, described how Chinese hamster ovary (CHO) cells have been used for over 30 years for production of proteins in high quantities by making a selected cell with a desired gene "happy" through positive growth factors.

The Summit concluded with a robust panel discussion from the day where there was considerable discussion about how long it takes for an analytic method to become a standard and how there is room for collaboration for next generation analytics. Given the 12-year exclusivity for new biologics, even if there were sharing of manufacturing information now, Kozlowski speculated, it will only help the originator industry grow better. For instance, Kozlowski thought there could be a social-network-type way to share information without any one group feeling left out or some singularity. Zingaro thought that there were few new manufacturing processes to share but that there was some sharing going on with analytics with room to grow. As a "stretch goal", Kozlowski thought that while the Agency is not at a point of saying clinical studies would not be required for market approval, in theory physical attributes could be linked to clinical outcomes. On a last point, it was agreed that better analytics at predicting quality would be a productive next step.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions